Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization
- International Medical Center, Tokyo (Japan)
- National Cancer Institute, Bethesda, MD (United States); and others
Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) is the initial and rate-limiting enzyme in the three-step pathway of uracil and thymine catabolism leading to the formation of {beta}-alanine and {beta}-aminobutyric acid, respectively. Several studies have demonstrated the importance of DPD in cancer patients, particularly in those lacking or having only low levels of activity. Patients exhibiting severe toxicity when administered 5-fluorouracil were shown to have low DPD activity. Studies of affected families demonstrated that the deficiency was inherited in an autosomal recessive pattern. DPD deficiency is one of several inherited disorders of pyrimidine metabolism, clinically termed thymine-uracil-uria. 14 refs., 1 fig.
- OSTI ID:
- 241057
- Journal Information:
- Genomics, Vol. 24, Issue 3; Other Information: PBD: Dec 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
ESR of spin-trapped radicals in aqueous solutions of dihydropyrimidine bases. [Gamma radiation]
Disease-causing mutations in exon 11 of the medium-chain Acyl-CoA dehydrogenase gene